Education
About Us
Working with TipRanks
Follow Us
Akero Therapeutics Inc (AKRO)
NASDAQ:AKRO
AKRO Analyst Ratings
Hold
1 Buy
7 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AKRO Stock 12 Month Forecast
Average Price Target
$59.71
▲(9.26% Upside)
| Highest Price Target$84.00 | Average Price Target$59.71 | Lowest Price Target$54.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TD Cowen
$58
Hold
6.13%
Upside
Reiterated
11/13/25
Canaccord Genuity
$54
Hold
-1.19%
Downside
Reiterated
11/13/25
Clear Street
$54
Hold
-1.19%
Downside
Reiterated
11/10/25
H.C. Wainwright
$72→$54
Hold
-1.19%
Downside
Downgraded
10/10/25
LifeSci Capital
$57→$58
Hold
6.13%
Upside
Downgraded
10/09/25
Jefferies
$56
Hold
2.47%
Upside
Downgraded
10/09/25
Wolfe Research
―
Hold
―
Downgraded
10/09/25
Morgan Stanley
$84
Buy
53.71%
Upside
Reiterated
09/18/25
Analysts Are Bullish on These Healthcare Stocks: Scholar Rock Holding (SRRK), Akero Therapeutics (AKRO)We believe the deal provides positive readthrough to Akero's EFX highlighting further interest in the FGF21 mechanism as a target for treating MASH. 11:51 AM GMTM Update 2 M Inc (AKRO.O) Our PT is derived from a discounted cash flow (DCF) analysis, including risk-adjusted revenues for EFX in NASH that assumes a 12.5% discount rate and a 0% terminal growth rate. Risks to Upside n Better than expected clinical data.
Bank of America Securities
$64
Buy
17.11%
Upside
Reiterated
08/25/25
Evercore ISI
$60
Buy
9.79%
Upside
Initiated
08/22/25
J.P. Morgan
$69→$68
Buy
24.43%
Upside
Reiterated
05/14/25
Westpark Capital
$72→$75
Buy
37.24%
Upside
Reiterated
02/28/25
Phillip Securities
$80
Buy
46.39%
Upside
Reiterated
02/28/25
UBS
$42→$109
Buy
99.45%
Upside
Reiterated
01/31/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TD Cowen
$58
Hold
6.13%
Upside
Reiterated
11/13/25
Canaccord Genuity
$54
Hold
-1.19%
Downside
Reiterated
11/13/25
Clear Street
$54
Hold
-1.19%
Downside
Reiterated
11/10/25
H.C. Wainwright
$72→$54
Hold
-1.19%
Downside
Downgraded
10/10/25
LifeSci Capital
$57→$58
Hold
6.13%
Upside
Downgraded
10/09/25
Jefferies
$56
Hold
2.47%
Upside
Downgraded
10/09/25
Wolfe Research
―
Hold
―
Downgraded
10/09/25
Morgan Stanley
$84
Buy
53.71%
Upside
Reiterated
09/18/25
Analysts Are Bullish on These Healthcare Stocks: Scholar Rock Holding (SRRK), Akero Therapeutics (AKRO)We believe the deal provides positive readthrough to Akero's EFX highlighting further interest in the FGF21 mechanism as a target for treating MASH. 11:51 AM GMTM Update 2 M Inc (AKRO.O) Our PT is derived from a discounted cash flow (DCF) analysis, including risk-adjusted revenues for EFX in NASH that assumes a 12.5% discount rate and a 0% terminal growth rate. Risks to Upside n Better than expected clinical data.
Bank of America Securities
$64
Buy
17.11%
Upside
Reiterated
08/25/25
Evercore ISI
$60
Buy
9.79%
Upside
Initiated
08/22/25
J.P. Morgan
$69→$68
Buy
24.43%
Upside
Reiterated
05/14/25
Westpark Capital
$72→$75
Buy
37.24%
Upside
Reiterated
02/28/25
Phillip Securities
$80
Buy
46.39%
Upside
Reiterated
02/28/25
UBS
$42→$109
Buy
99.45%
Upside
Reiterated
01/31/25
Best Analysts Covering Akero Therapeutics
1 Month
xxx
Success Rate
8/10 ratings generated profit
Average Return
+12.25%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +12.25% per trade.
3 Months
xxx
Success Rate
10/15 ratings generated profit
Average Return
+8.81%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +8.81% per trade.
1 Year
Success Rate
8/10 ratings generated profit
Average Return
+56.28%
reiterated a buy rating 7 months ago
Copying Eric Joseph's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +56.28% per trade.
2 Years
xxx
Success Rate
14/15 ratings generated profit
Average Return
+62.45%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 93.33% of your transactions generating a profit, with an average return of +62.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AKRO Analyst Recommendation Trends
Rating
May 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
8
13
17
9
4
Buy
5
7
6
3
0
Hold
0
0
1
8
11
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
20
24
20
15
Each month's total comprises the sum of three months' worth of ratings.
AKRO Financial Forecast
AKRO Stock Forecast FAQ
What is AKRO’s average 12-month price target, according to analysts?
Based on analyst ratings, Akero Therapeutics Inc’s 12-month average price target is 59.71.
What is AKRO’s upside potential, based on the analysts’ average price target?
Akero Therapeutics Inc has 9.26% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AKRO a Buy, Sell or Hold?
Akero Therapeutics Inc has a consensus rating of Hold which is based on 1 buy ratings, 7 hold ratings and 0 sell ratings.
What is Akero Therapeutics Inc’s price target?
The average price target for Akero Therapeutics Inc is 59.71. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $84.00 ,the lowest forecast is $54.00. The average price target represents 9.26% Increase from the current price of $54.65.
The highest analyst price target is $84.00 ,the lowest forecast is $54.00. The average price target represents 9.26% Increase from the current price of $54.65.
What do analysts say about Akero Therapeutics Inc?
Akero Therapeutics Inc’s analyst rating consensus is a Hold. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of AKRO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.